Glycorex-aktien är noterad och handlas på börsen Nordic Growth Market (NGM).
Glycorex Transplantation AB noterades på NGM Equity Stockholm 2001.
Symbol: GTAB B
When life starts again
Glycosorb®-ABO enables blood group incompatible transplants. Glycosorb®-ABO reduce anti-A/B antibodies in human plasma through A/B antigen specific binding. Glycosorb®-ABO has been used clinically since 2001. To date, transplant centres on four continents have treated more than 3,000 adult and paediatric patients.
Reduced health-care costs
Transplantation reduces health-care costs. In Sweden it is estimated that every successful kidney transplant saves a total of approximately 5 million Swedish kronor over a ten-year period compared with giving dialysis.
The Glycorex Group possesses unique know-how and proficiency in the fields of biologically active carbohydrate substances and extracorporeal blood treatment. This provides the foundation for the development work that the subsidiaries Glycoprobe and Glycorex UBP are doing in the fields of autoimmune diseases and universal blood plasma respectively.
The Glycorex Website (www.glycorex.se) contains information about products, which may or may not be available in any particular country, and if available, have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws, regulations, and medical practices governing the communication of medical or other information about medical products on the Internet. Nothing herein should be construed as a solicitation or promotion for any product, which is not authorized by the laws and regulations of the state or country where the reader resides. No Glycorex products are available for sales in the US at this point in time.